Kriya Announces Three Presentations at the 2024 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting – Kriya is developing KRIYA-825 as a potential one-time gene therapy expressing a fusion protein inhibiting the activity of complement C3 and C5 for the treatment of Geographic Atrophy – PALO...

Kriya Provides Update on Pipeline Progress Ahead of Company Presentation at 42nd Annual J.P. Morgan Healthcare Conference – Kriya anticipates up to 5 programs to enter clinic by the end of 2025 – – Current pipeline of gene therapies for common diseases spans three major therapeutics areas: ophthalmology, metabolic...

Kriya Announces Exclusive License and Collaboration Agreement with Everads to Advance Gene Therapies for Prevalent Diseases in Ophthalmology Including Geographic Atrophy – Everads' next generation suprachoroidal delivery technology enables targeted drug delivery to the retina, which Kriya intends to use for multiple ophthalmology gene therapy product candidates – ...